Skip to main content

Table 2 A comparison of clinical end-point data

From: RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer – the S.U.R.G.U.V.A.N.T. trial

  Placebo (n = 28) Taurolidine (n = 32) p-value
Pain Day 1 2.5 1.8 0.391
Day 2 1.9 2 0.873
Day 3 1.9 1 0.179
Time to bowel function (hrs)   39 34 0.32
Infective complication   8 4 0.19
 Surgical site infection   5 1 0.09
 Anastomotic leak   2 1 0.59
 Other   0 2 0.49